期刊的影响因子--文章列表

期刊文章列表
FengjuanJiang，HuiLiu，FengpingPeng，ZhaoyunLiu，KaiDing，JiaSong，LijuanLi，JinChen，QingShao，SiyangYan，KimDeVeirman，KarinVanderkerken，RongFu（Department of Hematology,Tianjin Medical University General Hospital；Department of Hematology and Immunology-Myeloma Center Brussels,Vrije Universiteit Brussel）.Complement C3a activates osteoclasts by regulating the PI3K/PDK1/SGK3 pathway in patients with multiple myeloma[J].Cancer Biology & Medicine,2021,第3期 GuangboKang，MinHu，HeRen，JiewenWang，XinCheng，RuoweiLi，BoYuan，YasmineBalan，ZixuanBai，HeHuang（Department of Biochemical Engineering,School of Chemical Engineering & Technology,Tianjin University；Key Laboratory of Systems Bioengineering （Ministry of Education）,Tianjin University；Department of Gastroenterology,Center of Tumor Immunology and Cytotherapy,Medical Research Center of The Affiliated Hospital of Qingdao University；Department of Chemical and Biological Engineering,University of Ottawa）.VHH212 nanobody targeting the hypoxia-inducible factor 1α suppresses angiogenesis and potentiates gemcitabine therapy in pancreatic cancer in vivo[J].Cancer Biology & Medicine,2021,第3期 AnjieZhu，PengYuan，NanlinHu，MingzhouLi，WenmiaoWang，XueWang，JianYue，JiayuWang，YangLuo，FeiMa，PinZhang，QingLi，BingheXu，ShanboCao，GiuseppeLippi，YoichiNaito，MohammedA.Osman，GustavoN.Marta，GianlucaFranceschini，ArmandoOrlandi（Department of Medical Oncology,National Cancer Center，National Clinical Research Center for Cancer，Cancer Hospital，Chinese Academy of Medical Sciences and Peking Union Medical College；Key Laboratory of Carcinogenesis and Translational Research （Ministry of Education，Beijing）,Department of Breast Oncology,Peking University Cancer Hospital & Institute；Department of VIP Medical Services,National Cancer Center，National Clinical Research Center for Cancer，Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College；Department of Pathology,National Cancer Center，National Clinical Research Center for Cancer，Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College；Acorn Med Biotechnology Co.,Ltd.；Section of Clinical Biochemistry,University Hospital of Verona；Department of Breast and Medical Oncology,National Cancer Center Hospital East；Clinical Oncology,General Organization for Teaching Hospitals）.Phase II study of apatinib in combination with oral vinorelbine in heavily pretreated HER2-negative metastatic breast cancer and clinical implications of monitoring ctDNA[J].Cancer Biology & Medicine,2021,第3期 WeiZhang，LipingSu，LihongLiu，YuhuanGao，QuanshunWang，HangSu，YuhuanSong，HuilaiZhang，JingShen，HongmeiJing，ShuyeWang，XinanCen，HuiLiu，AichunLiu，ZengjunLi，JianminLuo，JianxiaHe，JingwenWang，O.A.O’Connor，DaobinZhou（Department of Hematology,Peking Union Medical College Hospital；Department of Hematology，Shanxi Provincial Cancer Hospital；Department of Hematology,Fourth Hospital of Hebei Medical University；Department of Hematology,Chinese PLA General Hospital；Department of Lymphoma,the 307 Hospital of PLA；Department of Lymphoma,Peking University Cancer Hospital and Institute；Department of Lymphoma,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy，Tianjin,Tianjin’s Clinical Research Center for Cancer；Department of Hematology,Beijing Friendship Hospital；Department of Hematology,Peking University Third Hospital；Department of Hematology,the First Affiliated Hospital of Harbin Medical University；Department of Hematology,Peking University First Hospital；Department of Hematology,Beijing Hospital；Department of Lymphoma,Harbin Medical University Cancer Hospital）.The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma:a prospective, multicenter, single arm, phase 1b/2 study[J].Cancer Biology & Medicine,2021,第3期 Brandon M. Bordeau， Joseph P. Balthasar（Department of Pharmaceutical Science,University at Buffalo）.Strategies to enhance monoclonal antibody uptake and distribution in solid tumors[J].Cancer Biology & Medicine,2021,第3期 XinWang，ZifeiPei，AasmaHossain，YutingBai，GongChen（Department of Biology,Huck Institutes of Life Sciences,Pennsylvania State University,University Park；GHM Institute of CNS Regeneration,Jinan University）.Transcription factor-based gene therapy to treat glioblastoma through direct neuronal conversion[J].Cancer Biology & Medicine,2021,第3期 LisiZeng，QuanxingLiao，HaoranZhao，ShengweiJiang，XianziYang，HongshengTang，QingjunHe，XianshengYang，ShuxianFang，JinfuHe，WeiwenCui，LaiqiangHuang，ShaohuaMa，ShuzhongCui（Institute of Oncology,Affiliated Cancer Hospital and Institute of Guangzhou Medical University；Department of Abdominal Surgery,Affiliated Cancer Hospital and Institute of Guangzhou Medical University；Institute of Biopharmaceutical and Health Engineering,Shenzhen International Graduate School,Tsinghua University；Tsinghua-Berkeley Shenzhen Institute （TBSI）,Tsinghua University；Shenzhen Key Laboratory of Gene and Antibody Therapy,Tsinghua University；Department of Medical Oncology,Affiliated Cancer Hospital and Institute of Guangzhou Medical University；Department of Bioengineering,University of California）.Raltitrexed as a synergistic hyperthermia chemotherapy drug screened in patient-derived colorectal cancer organoids[J].Cancer Biology & Medicine,2021,第3期 TaoChen，FeiWang，ShupeiWei，YingjieNie，XiaotaoZheng，YuDeng，XubinZhu，YuezhenDeng，NanshanZhong，ChengzhiZhou（State Key Laboratory of Respiratory Disease,National Clinical Research Center for Respiratory Disease,Guangzhou Institute of Respiratory Health,the First Affiliated Hospital of Guangzhou Medical University；NHC Key Laboratory of Pulmonary Immunological Diseases,Clinical Research Lab Center,Guizhou Provincial People’s Hospital；Longgang Central Hospital of Shenzhen,Affiliated Shenzhen Longgang Central Hospital of Zunyi Medical College；Center for Molecular Medicine,Xiangya Hospital,Central South University）.FGFR/RACK1 interacts with MDM2, promotes P53 degradation, and inhibits cell senescence in lung squamous cell carcinoma[J].Cancer Biology & Medicine,2021,第3期 Diya Liu， Lin Fang（Department of Thyroid and Breast Diseases,Shanghai Tenth People’s Hospital）.Current research on circular RNAs and their potential clinical implications in breast cancer[J].Cancer Biology & Medicine,2021,第3期 ChengmingLiu，SihuiWang，SufeiZheng，XinfengWang，JianbinHuang，YuanyuanLei，ShuangshuangMao，XiaoliFeng，NanSun，JieHe（Department of Thoracic Surgery,National Cancer Center，National Clinical Research Center for Cancer，Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College；Department of Pathology,National Cancer Center，National Clinical Research Center for Cancer，Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College）.A novel recurrence-associated metabolic prognostic model for risk stratification and therapeutic response prediction in patients with stage I lung adenocarcinoma[J].Cancer Biology & Medicine,2021,第3期 WinnieYeo，LeungLi，ThomasKHLau，KwaiTLai，VickyTCChan，KwanHWong，ChristopherCHYip，ElizabethPang，MaggieCheung，VivianChan，CarolCHKwok，JoyceJSSuen，FrankieKFMo（Department of Clinical Oncology,Prince of Wales Hospital,Faculty of Medicine,Hong Kong Cancer Institute；State Key Laboratory of Translational Oncology,The Chinese University of Hong Kong；Department of Clinical Oncology,Princess Margaret Hospital）.Identification of optimal contemporary antiemetic prophylaxis for doxorubicin-cyclophosphamide chemotherapy in Chinese cancer patients: post-hoc analysis of 3 prospective studies[J].Cancer Biology & Medicine,2021,第3期 MeitingChen，ZhaoWang，XiaojieFang，YuyiYao，QuanguangRen，ZegengChen，YingTian，FeiPan，XiaoqianLi，ZhimingLi，QingqingCai，HeHuang，TongyuLin（Department of Medical Oncology,Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine；Senior Ward，Phase Ⅰ Clinical Trial Ward,Sichuan Cancer Hospital & Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology of China）.Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma[J].Cancer Biology & Medicine,2021,第3期 EvgeniyaV.Dolgova，OlegM.Andrushkevich，PolinaE.Kisaretova，AnastasiaS.Proskurina，GenrikhS.Ritter，TatyanaD.Dubatolova，MargaritaV.Romanenko，OlegS.Taranov，YaroslavR.Efremov，EvgeniyL.Zavyalov，AlexandrV.Romaschenko，SergeyV.Mishinov，SvetlanaS.Kirikovich，EvgeniyV.Levites，EkaterinaA.Potter，AlexandrA.Ostanin，ElenaR.Chernykh，StanislavYu.Roshchin，AnatoliyV.Bervitskiy，GalinaI.Moysak，JamilA.Rzaev，SergeyS.Bogachev（Institute of Cytology and Genetics SB RAS；A.I.Evdokimov Moscow State University of Medicine and Dentistry；Institute of Molecular and Cellular Biology；Novosibirsk State University；The State Research Center of Virology and Biotechnology "Vector"；First Department of Neurosurgery,Ya.L.Tsivian Novosibirsk Research Institute of Traumatology and Orthopaedics；Institute of Fundamental and Clinical immunology；Sklifosovsky Research Institute of Emergency Medicine；Federal Center of Neurosurgery）.Efficacy of the new therapeutic approach in curing malignant neoplasms on the model of human glioblastoma[J].Cancer Biology & Medicine,2021,第3期 TianqingChu，JunLu，MinghongBi，HelongZhang，WuZhuang，YanYu，JianhuaShi，ZhendongChen，XiaochunZhang，QisenGuo，QuanLiu，HuijuanWu，JianFang，YiHu，XiuwenWang，CuicuiHan（Department of Pulmonary Medicine,Shanghai Chest Hospital,Shanghai Jiao Tong University；Department of Oncology,The First Affiliated Hospital of Bengbu Medical College；Department of Oncology,Tangdu Hospital,Air Force Medical University of PLA；Department of Medical Thoracic Oncology,Fujian Cancer Hospital,Fujian Medical University Cancer Hospital；Department of Oncology,Harbin Medical University Cancer Hospital；Department of Oncology,Linyi Cancer Hospital；Department of Oncology,The Second Hospital of Anhui Medical University；Department of Oncology,The Affiliated Hospital of Qingdao University；Department of Internal Medicine,Shandong Cancer Hospital Affiliated to Shandong University；Department of Oncology,Affiliated Hospital of Jiang Nan University；Department of Internal Medicine,Henan Province Tumor Hospital,Zhengzhou University；Department of Thoracic Oncology Ⅱ,Peking University Cancer Hospital and Institute；Department of Oncology,Chinese PLA General Hospital）.Equivalent efficacy study of QL1101 and bevacizumab on untreated advanced non-squamous non-small cell lung cancer patients: a phase 3 randomized, double-blind clinical trial[J].Cancer Biology & Medicine,2021,第3期 Huizhi Sun^1,2，Danfang Zhang²，Chongbiao Huang¹，Yuhong Guo¹，Zhao Yang²，Nan Yao²，Xueyi Dong²，Runfen Cheng¹，Nan Zhao²，Jie Meng²，Baocun Sun²，Jihui Hao¹（Tianjin Medical University Cancer Institute and Hospital，National Clinical Research Center for Cancer，Key Laboratory of Cancer Prevention and Therapy，Tianjin，Tianjin’s Clinical Research Center for Cancer；Department of Pathology，School of Basic Medical Science，Tianjin Medical University）.Hypoxic microenvironment induced spatial transcriptome changes in pancreatic cancer[J].Cancer Biology & Medicine,2021,第2期 Xianxian Wu¹，Hongdian Zhang¹，Zhilin Sui¹，Yang Wang²，Zhentao Yu¹（Departments of Esophageal Cancer，Tianjin Medical University Cancer Institute and Hospital，National Clinical Research Center for Cancer，Key Laboratory of Cancer Prevention and Therapy，Tianjin，Tianjin’s Clinical Research Center for Cancer；Department of Immunology，Tianjin Medical University Cancer Institute and Hospital，National Clinical Research Center for Cancer，Key Laboratory of Cancer Prevention and Therapy，Tianjin，Tianjin’s Clinical Research Center for Cancer）.The biological role of the CXCL12/CXCR4 axis in esophageal squamous cell carcinoma[J].Cancer Biology & Medicine,2021,第2期 Xubo Zhao¹，Jie Bai¹，Wenjing Yang²（Green Catalysis Center and College of Chemistry，Zhengzhou University；Department of Anesthesiology，The First Affiliated Hospital of Zhengzhou University）.Stimuli-responsive nanocarriers for therapeutic applications in cancer[J].Cancer Biology & Medicine,2021,第2期 Ying Xue¹，Yuting Gao¹，Fanling Meng^1,2，Liang Luo^1,2,3（National Engineering Research Center for Nanomedicine，College of Life Science and Technology，Huazhong University of Science and Technology；Hubei Key Laboratory of Bioinorganic Chemistry and Materia Medica，School of Chemistry and Chemical Engineering，Huazhong University of Science and Technology；Research Institute of Huazhong University of Science and Technology in Shenzhen）.Recent progress of nanotechnology-based theranostic systems in cancer treatments[J].Cancer Biology & Medicine,2021,第2期 Rui Li^1,2，Zhimin Chen¹，Zhifei Dai²，Yingjie Yu³（College of Life Science and Technology，Beijing University of Chemical Technology；Department of Biomedical Engineering，College of Engineering，Peking University；Institute of Translational Medicine，The First Affiliated Hospital of Shenzhen University，Shenzhen Second People’s Hospital）.Nanotechnology assisted photo- and sonodynamic therapy for overcoming drug resistance[J].Cancer Biology & Medicine,2021,第2期 Chunhua Luo^1,2，Zhongjie Ding¹，Yun Tu¹，Jiao Tan³，Qing Luo¹，Guanbin Song¹（Key Laboratory of Biorheological Science and Technology，Ministry of Education，College of Bioengineering，Chongqing University；Institute of Pathology and Southwest Cancer Center，Southwest Hospital，Third Military Medical University (Army Medical University)，Key Laboratory of Tumor Immunopathology，Ministry of Education of China；School of Pharmacy，Chongqing Medical and Pharmaceutical College）.Biomaterial-based platforms for cancer stem cell enrichment and study[J].Cancer Biology & Medicine,2021,第2期 Denise Drago¹，Annapaola Andolfo¹，Ettore Mosca²，Alessandro Orro²，Luigi Nocera³，Vito Cucchiara³，Matteo Bellone⁴，Francesco Montorsi³，Alberto Briganti³（ProMeFa，Proteomics and Metabolomics Facility，Center for Omics Sciences (COSR)，IRCCS San Raffaele Scientific Institute；Institute of Biomedical Technologies，National Research Council (CNR)；Department of Urology and Division of Experimental Oncology，Urological Research Institute (URI)，IRCCS San Raffaele Scientific Institute；Division of Immunology，Transplantation and Infectious Diseases，IRCCS San Raffaele Scientific Institute）.A novel expressed prostatic secretion (EPS)-urine metabolomic signature for the diagnosis of clinically significant prostate cancer[J].Cancer Biology & Medicine,2021,第2期 Zhen Ni^1,2，Wenquan Lu³，Qi Li⁴，Chuan Han⁴，Ting Yuan⁵，Nina Sun⁶，Yongquan Shi¹（State Key Laboratory of Cancer Biology & Institute of Digestive Diseases，Xijing Hospital，Air Force Medical University of PLA；Department of Gastroenterology，General Hospital of Western Theater Command；Department of Gastroenterology，First Affiliated Hospital of Zhengzhou University；Department of Endocrinology，General Hospital of Western Theater Command；Department of Gastroenterology，989 Hospital of the People’s Liberation Army；Department of Gastroenterology，First Affiliated Hospital of Xi’an Medical College）.Analysis of the HNF4A isoform-regulated transcriptome identifies CCL15 as a downstream target in gastric carcinogenesis[J].Cancer Biology & Medicine,2021,第2期 Meina Jiang^1,2，Shuai Fang^1,2，Xiaodong Zhao^1,3，Chengwei Zhou^1,3，Zhaohui Gong^1,2（Department of Biochemistry and Molecular Biology，Ningbo University School of Medicine；Zhejiang Province Key Laboratory of Pathophysiology，Ningbo University School of Medicine；Department of Thoracic Surgery，The Affiliated Hospital of Ningbo University School of Medicine）.Epithelial-mesenchymal transition-related circular RNAs in lung carcinoma[J].Cancer Biology & Medicine,2021,第2期 Mingwei Chen¹，Xuedong Wei¹，Xiu Shi²，Le Lu¹，Guangbo Zhang^1,3，Yuhua Huang¹，Jianquan Hou¹（Department of Urology，The First Affiliated Hospital of Soochow University；Department of Obstetrics and Gynecology，The First Affiliated Hospital of Soochow University；Jiangsu Institute of Clinical Immunology，The First Affiliated Hospital of Soochow University，Jiangsu Key Laboratory of Clinical Immunology，Soochow University，Jiangsu Key Laboratory of Gastrointestinal Tumor Immunology）.LncRNA HIF1A-AS2 accelerates malignant phenotypes of renal carcinoma by modulating miR-30a-5p/SOX4 axis as a ceRNA[J].Cancer Biology & Medicine,2021,第2期 Yan Song¹，Juxiang Xiao²，Wentao Fang³，Ping Lu⁴，Qingxia Fan⁵，Yongqian Shu⁶，Jifeng Feng⁷，Shu Zhang⁸，Yi Ba⁹，Yang Zhao¹⁰，Ying Liu¹¹，Chunmei Bai¹²，Yuxian Bai¹³，Yong Tang¹⁴，Jie He¹⁵，Jing Huang¹（Department of Medical Oncology，National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital，Chinese Academy of Medical Sciences and Peking Union Medical College；Department of Medical Oncology，First Hospital of Xi’an Jiaotong University；Department of Thoracic Surgery，Shanghai Chest Hospital，Shanghai Jiao Tong University；Department of Medical Oncology，First Affiliated Hospital of Xinxiang Medical University；Department of Oncology，The First Affiliated Hospital of Zhengzhou University；Department of Oncology，The First Affiliated Hospital of Nanjing Medical University；Department of Medical Oncology，Jiangsu Cancer Hospital；Department of Medical Oncology，Shandong Cancer Hospital；Department of Medical Oncology，Tianjin Medical University Cancer Institute and Hospital，National Clinical Research Center for Cancer，Key Laboratory of Cancer Prevention and Therapy，Tianjin，Tianjin’s Clinical Research Center for Cancer；Department of Biostatistics，School of Public Health，Nanjing Medical University；Department of Medical Oncology，Henan Cancer Hospital；Department of Oncology，Peking Union Medical College Hospital，Chinese Academy of Medical Sciences；Department of Medical Oncology，Harbin Medical University Cancer Hospital；Department of Gastroenterology，Affiliated Tumor Hospital，Xinjiang Medical University；Department of Thoracic Surgical Oncology，National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital，Chinese Academy of Medical Sciences and Peking Union Medical College）.The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma[J].Cancer Biology & Medicine,2021,第2期 Li Tu¹，Zheng Luo¹，Yun-Long Wu¹，Shuaidong Huo¹，Xing-Jie Liang²（Fujian Provincial Key Laboratory of Innovative Drug Target Research，School of Pharmaceutical Sciences，Xiamen University；CAS Center for Excellence in Nanoscience，CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety，National Center for Nanoscience and Technology）.Gold-based nanomaterials for the treatment of brain cancer[J].Cancer Biology & Medicine,2021,第2期 Qiujuan Huang¹，Tongyuan Qu¹，Lisha Qi¹，Changxu Liu²，Yuhong Guo¹，Qianru Guo¹，Guangning Li¹，Yalei Wang¹，Wenshuai Zhang¹，Wei Zhao¹，Danyang Ren¹，Leina Sun¹，Shengguang Wang³，Bin Meng¹，Baocun Sun¹，Bin Zhang⁴，Wenjuan Ma⁵，Wenfeng Cao¹（Department of Pathology，Tianjin Medical University Cancer Institute and Hospital，National Clinical Research Center for Cancer，Key Laboratory of Cancer Prevention and Therapy，Tianjin，Tianjin’s Clinical Research Center for Cancer；Department of Pathology，Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital；Department of Lung Cancer，Tianjin Lung Cancer Center；Department of Breast Cancer；Department of Breast Imaging，Key Laboratory of Breast Cancer Prevention and Therapy，Tianjin Medical University Cancer Institute and Hospital，National Clinical Research Center for Cancer，Key Laboratory of Cancer Prevention and Therapy，Tianjin，Tianjin’s Clinical Research Center for Cancer）.A nomogram-based immune-serum scoring system predicts overall survival in patients with lung adenocarcinoma[J].Cancer Biology & Medicine,2021,第2期 Jie Liang^1,2，Xiao Zhao^1,2（CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety & CAS Center for Excellence in Nanoscience，National Center for Nanoscience and Technology of China；University of Chinese Academy of Sciences）.Nanomaterial-based delivery vehicles for therapeutic cancer vaccine development[J].Cancer Biology & Medicine,2021,第2期 Jiaqi Wang^1,2，Yi Zhang¹，Lianyu Liu^1,2，Ting Yang¹，Jun Song^1,2（Department of General Surgery，The Affiliated Hospital of Xuzhou Medical University；Institute of Digestive Diseases of Xuzhou Medical University）.Circular RNAs: new biomarkers of chemoresistance in cancer[J].Cancer Biology & Medicine,2021,第2期 Xuan Zhao^1,2，Shasha Liu^1,2，Xinfeng Chen^1,2，Jianyi Zhao³，Feng Li^1,2，Qitai Zhao^1,2，Tan Xie⁴，Lan Huang^1,2，Zhen Zhang^1,2，Yu Qi³，Yang Yang³，Song Zhao³，Yi Zhang^1,2,5,6（Biotherapy Center，The First Affiliated Hospital of Zhengzhou University；Cancer Center，The First Affiliated Hospital of Zhengzhou University；Department of Thoracic Surgery，The First Affiliated Hospital of Zhengzhou University；Department of Pediatric Surgery，The First Affiliated Hospital of Zhengzhou University；School of Life Sciences，Zhengzhou University；Henan Key Laboratory for Tumor Immunology and Biotherapy）.L1CAM overexpression promotes tumor progression through recruitment of regulatory T cells in esophageal carcinoma[J].Cancer Biology & Medicine,2021,第2期首页上一页 1 2 3 下一页尾页共有3页，转到页

期刊文章列表